Continuous exposure to low-dose cisplatin and apoptosis

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 10, 2005, Pages 1954-1957

  Kishimoto, Shuichi ^a   Kawazoe, Yuji ^a   Ikeno, Mako ^a   Fukushima, Shoji ^a   Takeuchi, Yoshikazu ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cisplatin (CDDP); Low dose

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE INHIBITOR; CISPLATIN; CYTOTOXIC AGENT; PEPTIDE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVITY; HEPATOMA CELL; LOW DRUG DOSE; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL LINE, TUMOR; CISPLATIN; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; G1 PHASE; LIVER NEOPLASMS, EXPERIMENTAL; RATS;

EID: 26444570297     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.28.1954     Document Type: Article

References (26)

1. Loehrer P. J., Einhorn L. H., Ann. Intern. Med., 100, 704-713 (1984).
2. Sorenson C. M., Eastman A., Cancer Res., 48, 6703-6707 (1988).
3. Shellard S. A., Fichtinger-Schepman A. M., Lazo J. S., Hill B. T., Anti-cancer Drugs, 4, 491-500 (1993).
4. Johnson S. W., Swiggard P. A., Handel L. M., Brennan J. M., Godwin A. K., Ozols R. F., Hamilton T. C., Cancer Res., 54, 5911-5916 (1994).
5. Evans D. L., Tilby M., Dive C., Cancer Res., 54, 1596-1603 (1994).
6. Eastman A., Cancer Cells, 2, 275-280 (1990).
7. Jordan P., Carmo-Fonseca M., Cell. Mol. Life Sci., 57, 1229-1235 (2000).
8. Gonzalez V. M., Fuertes M. A., Alonso C., Perez J. M., Mol. Pharmacol., 59, 657-663 (2001).
9. Ozawa S., Sugiyama Y., Mitsuhashi Y., Kobayashi T., Inaba M., Cancer Chemother. Pharmacol., 21, 185-190 (1988).
10. Ozawa S., Sugiyama Y., Mitsuhashi J., Inaba M., Cancer Res., 49, 3823-3828 (1989).
11. Morazzoni F., Canevali C., Zucchetti M., Caroli S., Alimonti A., Petrucci F., Giudice G., Masoni E., Bedini A. V., J. Cancer Res. Clin. Oncol., 124, 37-43 (1998).
12. Kurihara N., Kubota T., Hoshiya Y., Otani Y., Kumai K., Kitajima M., J. Surg. Oncol., 60, 238-241 (1995).
13. Nakashima M., Ichinose K., Kanematsu T., Masunaga T., Ohya Y., Ouchi T., Tomiyama N., Sasaki H., Ichikawa M., Biol. Pharm. Bull., 22, 756-761 (1999).
14. Kishimoto S., Miyazawa K., Fukushima S., Takeuchi Y., Jpn. J. Cancer Res., 91, 99-104 (2000).
15. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Karydas A. G., Ithakissios D. S., J. Control Release, 79, 123-135 (2002).
16. Nishiyama N., Okazaki S., Cabral H., Miyamoto M., Kato Y., Sugiyama Y., Nishio K., Matsumura Y., Kataoka K., Cancer Res., 63, 8977-8983 (2003).
17. Kishimoto S., Noguchi T., Yamaoka T., Fukushima S., Takeuchi Y., Biol. Pharm. Bull., 23, 637-640 (2000).
18. Kishimoto S., Noguchi T., Yamaoka T., Fukushima S., Takeuchi Y., Biol. Pharm. Bull., 23, 487-491(2000).
19. Liu X., Li P., Widlak P., Zou H., Luo X., Garrard W. T., Wang X., Proc. Natl. Acad. Sci. U.S.A., 95, 8461-8466 (1998).
20. Nagata S., Exp. Cell Res., 256, 12-18 (2000).
21. Widlak P., Acta Biochim. Pol., 47, 1037-1044 (2000).
22. Jamieson E. R., Lippard S. J., Chem. Rev., 99, 2467-2498 (1999).
23. LeRoy A. F., Thompson W. C., J. Natl. Cancer Inst., 81, 427-436 (1989).
24. Nagai N., Kinoshita M., Ogata H., Tsujino D., Wada Y., Someya K., Ohno T., Masuhara K., Tanaka Y., Kato K., Nagai H., Yokoyama A., Kurita Y., Cancer Chemother. Pharmacol., 39, 131-137 (1996).
25. Tacka K. A., Szalda D., Souid A. K., Goodisman J., Dabrowiak J. C., Chem. Res. Toxicol., 17, 1434-1444 (2004).
26. Siddik Z. H., Oncogene, 22, 7265-7279 (2003).